Truist Securities Maintains Buy on OrthoPediatrics, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Buy rating on OrthoPediatrics (NASDAQ:KIDS) and increased the price target from $35 to $39.
December 22, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OrthoPediatrics' stock rating has been reaffirmed as Buy by Truist Securities, with a raised price target from $35 to $39, indicating a positive outlook on the stock.
The reaffirmation of a Buy rating and an increase in the price target typically signal confidence in the company's future performance and can lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100